Shots:

• Kyowa will terminate its sales and marketing activities for ASACOL on Mar 31- 2020. Zeria to get exclusive full rights for sales and marketing for ASACOL from Apr 01- 2020
• In Jan 2007- Kyowa and Zeria signed an exclusive co-development and co-marketing agreement for ASACOL in Japan
• ASACOL (mesalazine) is an anti-inflammatory enteric-coated tablet involved in releasing active ingredient mesalazine pH dependently and was launched in Japan in Dec 2009- targeted to treat ulcerative colitis in Japan

Click here to read full press release/ article | Ref: Kyowa Kirin | Image: Pharma World